Targeted Medical Pharma Inc · OTC:TRGM
Targeted Medical Pharma — Investor Presentation (April 2013)
31 slides from Targeted Medical Pharma's investor presentation, Apr 23, 2013
Slide 1: Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology
Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology April 2013
Slide 2: Safe Harbor Statement
Safe Harbor Statement This document does not constitute or form part of an invitation or recommendation to subscribe for or purchase any securities of Targeted Medical Pharma, Inc . (“Targeted Medical Pharma”, “TMP” or “the Company”) . This document was prepared exclusively for the benefit and inter
Slide 3: Investment Highlights
Investment Highlights TARGETED MEDICAL PHARMA 3 A Biotech Leader in the Rx - Only, Medical Foods Market
Slide 4: Biotechnology company overview
Biotechnology company founde: Low-cost development platform A technology that is applicable to multiple diseases A safe option for the treatment of common medical condi Ten core proprietary Rx-Only Medical Foods Strong product pipeline and patent portfolio Present and Future Distribution Through Mul
Slide 5: About Rx-Only Medical Foods
©) About Rx-Only Medical Foods Medical foods are FDA-regulated medications intended for the dietary management of a disease that has distinctive nutritional needs that cannot be met by normal diet alone as defined in the Food and Drug Administration's 1988 Orphan Drug Act Amendments. Must make a dis
Slide 6: Targeted Cellular Technology
Five - component System Stimulates Uptake and Utilization of Amino Acids Targeted Cellular Technology TARGETED MEDICAL PHARMA 6
Slide 7: Product Rollout and Pipeline
*First Known Oral Stimulation of Stem Cells ** Cumulative for 2010 to 2012, and including convenience kits Product Rollout and Pipeline TARGETED MEDICAL PHARMA 7 Product Indication In Development (est. launch date) Clinical Trials (est. launch date) Actively Promoted (% of monthly doses)** Theramine
Slide 8: Consistent Biotechnology Development Track Record
TARGETED MEDICAL PHARMA Consistent Biotechnology Development Track Record 8 • Obesity and Metabolic Syndrome with Apptrim® (2001) • Hypertension with Hypertensa® (2003) • Sleep disorders with Sentra PM® and GABAdone® (2003) • Cognitive dysfunction with Sentra AM® (2003) • Osteoarthritis with Trepado
Slide 9: Medical Foods: Meeting Physician & Patient Demand
Improve Patient Outcomes Reduce Negative Side Effects Lower Costs Nutritional Management of Chronic Disease Generally Recognized as Safe Clinical Trials Demonstrate Efficacy Reduce Dosage of Opiates Improved Adherence SOLUTIONS NEEDS Medical Foods: Meeting Physician & Patient Demand TARGETED MEDICAL
Slide 10: The Basis for Low-Cost Research and Development
The Basis for Low - Cost Research and Development Exemption No safety trials, only efficacy must be demonstrated Registration 60 products registered with the FDA Categorization 2 Categorized as an old drug Regulation 1 Regulated under the FDA’s medical food definition 1 Regulation • Must be administ
Slide 11: Two Platform Technologies
Two Platform Technologies TARGETED MEDICAL PHARMA 11 Targeted Amino Acid Technology (TAT) Targeted Cellular Technology (TCT)
Slide 12: Reduction in C-Reactive Protein with Theramine
Reduction in C - Reactive Protein with Theramine® TARGETED MEDICAL PHARMA 12 Primary Uses Improvement in Inflammatory Markers Source: Shell, et al.,“A Double - Blind Controlled Trial of a Single Dose Naproxen and an Amino Acid Medical Food Theramine for the Treatment of Low Back Pain”; American Jour
Slide 13: Clinical Trial: Theramine with Naproxen
Primary Uses Improvement in Disability Index Clinical Trial: Theramine® with Naproxen (Theraproxen®) TARGETED MEDICAL PHARMA 13 Source: Shell, et al.,“A Double - Blind Controlled Trial of a Single Dose Naproxen and an Amino Acid Medical Food Theramine for the Treatment of Low Back Pain”; American Jo
Slide 14: Clinical Trial: Theramine with Ibuprofen
Improvement in Blood Concentration of Amino Acids Primary Uses Clinical Trial: Theramine® with Ibuprofen (Theraprofen®) TARGETED MEDICAL PHARMA 14 Source: Shell, et al., “A Double - Blind Controlled Trial of a Single Dose Ibuprofen and an Amino Acid Medical Food Theramine for the Treatment of Low Ba
Slide 15: Clinical Trial: Theramine with Ibuprofen
Clinical Trial: Theramine® with Ibuprofen (Theraprofen®) TARGETED MEDICAL PHARMA 15 0.09 - 6.15 - 9.08 -10 -8 -6 -4 -2 0 2 Ibuprofen Theramine Combination Change in Visual Analog Pain Scale (VAS) from Day 1 to day 28 (negative change indicates reduction in pain) Roland Morris Score After 28 Days n=1
Slide 16: Pharmacoeconomic Analysis of Theramine
Pharmacoeconomic Analysis of Theramine TARGETED MEDICAL PHARMA Over 40,000,000 capsules administered with no reported G.I. bleeds or deaths. Use of Theramine Potentially Reduces the Cost of Care by >30% 16 Source: Silver DS, et al. Theramine (A Medical Food) Versus Non - Steroidal Anti Inflammatory
Slide 17: Clinical Trial: Sentra PM and Trazodone
Clinical Trial: Sentra PM® and Trazodone (Trazamine®) Improvement in Sleep Quality Primary Uses TARGETED MEDICAL PHARMA 17 1 Pittsburgh Sleep Quality Index Source: Shell, et al., “Sentra PM and Trazodone for the management of Sleep Disorders” Journal of Central Nervous System Disease; 2012:4
Slide 18: Clinical Trial: Sentra PM and Trazodone
Clinical Trial: Sentra PM® and Trazodone (Trazamine®) TARGETED MEDICAL PHARMA 18 2.80 18.86 - 12.64 - 32.27 -40 -30 -20 -10 0 10 20 30 Placebo Trazodone Sentra PM Combination Change in Visual Analog Scale (VAS) Negative change indicates reduced grogginess Trazamine Study: Subject Reported AM Groggin
Slide 19: Stem Cells: Initial Data on ESS-1818
- 20,000 40,000 60,000 80,000 100,000 120,000 1 2 5 7 17 Effect of ESS - 1818 on Reticulocyte Count in Healthy Volunteers 1 Reticulocytes Stimulation of Red Blood Cell Precursors 1 Effect on one patient in pre - clinical trials. Pre - clinical trials resulted in an 80% response rate. Treatment Initi
Slide 20: Intellectual Property Highlights
Intellectual Property Highlights TARGETED MEDICAL PHARMA 1 Targeted Cellular Technology® is a five - component system the stimulates the uptake and utilization of amino acids. It enables efficacy from microgram quantities of amino acids. *First Known Oral Stimulation of Stem Cells 20 Seven Issued Pa
Slide 21: Financials and Team
Innovators in Pharmaceutical Technology Financials and Team
Slide 22: Financial Snapshot – Fiscal Year 2012
Financial Snapshot – Fiscal Year 2012 TARGETED MEDICAL PHARMA 22 Summary Year ended December 31, 2012 Revenue $7.3 million Operating Expenses $10.2 million Shares Outstanding 23.0 million Shares: Fully Diluted 27.1 million Other Information Comments Cash and Cash Equivalents $0.3 million Contract Re
Slide 23: Contract Receivables
Shipments : Contract Receivables Collections : Recognized Revenue Contract Receivables are amounts due but not yet recognized as revenue Monthly collections are approximately 1.5% to 2.0% Collected amounts impact bottom - line operating revenue almost directly Contract receivables are constantly rej
Slide 24: Improving the Reimbursement Mix
Improving the Reimbursement Mix TARGETED MEDICAL PHARMA 24 75% 20% 5% 60% 35% 5% 55% 30% 5% 10% 35% 35% 15% 15% 2011 2012 2013 2014 Improving Reimbursement Diversification Workers Compensation Private Insurance Medicare Part D DOD / VA
Slide 25: Quarterly Revenue Growth
Quarterly Revenue Growth TARGETED MEDICAL PHARMA 25 $- $500 $1,000 $1,500 $2,000 $2,500 $3,000 Q1'12 Q2'12 Q3'12 Q4'12 Q1'13 $1,375 $1,448 $2,077 $2,396 $2,811 Revenue Growth ($000's) 2012 Audited, 2013 Unaudited
Slide 26: Reimbursement Channels
nbursement Channels Channel Types. Top Medical Plans Government Reimbursement © Workers’ Compensation @ Private Insurance © Medicare Secondary Insurance Plans @ Rx Solutions @% Medco caremark 1 Catamaran (Walgreens) @% Medimpact Express Scripts Mi cigna © BlueCross/Blue Shield © United Healthcare Ae
Slide 27: Growth Objectives
Growth Objectives TARGETED MEDICAL PHARMA 27 2013 Objectives Turn long term contract receivables into cash and short term receivables Cambridge contract signed in Nov ’12, now performing Grow sales to the VA, DOD and Indian Health Service Achieved listing on the Federal Supply Schedule and orders st
Slide 28: Key Management
Key Management TARGETED MEDICAL PHARMA 28 William Shell, M.D. Co - Founder, CEO and Chief Science Officer Extensive background in science and medicine, including roles as director of the Keesler Air Force Base Coronary Care Unit an d d irector of the Cardiovascular Biochemistry Research Laboratories
Slide 29: Board of Directors
Independent: Maurice J. DeWald - Chairman of the Board and Compensation Committee • Retired board member and regional managing partner at KPMG • Serves as board director for several healthcare companies Kerry Weems - Chair of Nominating and Corporate Governance Committees • Former administrator for
Slide 30: Investment Considerations
Investment Considerations HIGH DEMAND PRODUCTS ADDRESSING LARGE MARKETS 1 GROWING ADOPTION OF MEDICAL FOODS 2 ROBUST PIPELINE 3 STRONG AND VALUABLE INTELLECTUAL PROPERTY PORTFOLIO 4 PROVEN SAFETY AND EFFICACY THROUGH CLINICAL TRIALS 5 LOW SIDE - EFFECT PROFILE 6 LOW - COST DEVELOPMENT PLATFORM / FAS
Slide 31: Contact
Contact 2980 Beverly Glen Circle, Suite 301 Los Angeles, CA 90077 Telephone: 310 - 474 - 9809 Fax: 310 - 531 - 7089 investors@tmedpharma.com Brand site: www.ptlcentral.com Company site: www.tmedpharma.com
Targeted Medical Pharma — Investor Presentation (April 2013) on 6ix